Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

• Status: Recruiting
• Trial end date: 2024-01-18
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation

Criteria

Inclusion Criteria:

• Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB 18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with vitiligo.

• Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.

• Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.

• Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.

• Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child.

• Ability to comprehend and willingness to sign an ICF or written informed consent of the parent(s) or legal guardian and written assent from the participant when possible.

Exclusion Criteria:

• Has been permanently discontinued from study treatment in the parent study for any reason.

• Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.

• Pregnant or breastfeeding woman.

• Participants who live with anyone participating in any current Incyte-sponsored ruxolitinib cream study.